Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewORYZON reports results and corporate update for quarter ended March 31, 2021
La compañía invierte 3,6 M€ en I+D sin impactos significativos derivados de la pandemia covid-19
-
New3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new t...
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications
-
NewYsios Capital invests in Cytoki Pharma
Biotech company Cytoki Pharma (Copenhagen, Denmark) develops new proteins based on interleukin 22 (IL-22) for the treatment of epithelial lesions
-
CompanyBME Growth
-
NewYsios Capital leads a 51 million euros investment in Adcendo
Adcendo (Copenhagen, Denmark), is a biotechnology company specializing in the development of immunoconjugated drugs for the treatment of certain types of cancer that do not respond to current
-
CompanyIllumina
-
CompanyCellab
-
NewFirst AI-designed drug for Huntington’s disease to enter clinical trials
In less than 12 months, the collaboration between Chemotargets, based in the Barcelona Science Park, and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of
-
NewPrivate investment in Spanish biotech firms up nearly 50% in 2020
This year saw over €150 million in private capital invested, compared to €103 million in 2019. Publicly traded biotech firms attracted over €70 million on capital markets, up 35% from 2019
-
-
EventEMBO Practical Course: Flow Cytometry of biological nano-particles for multi-omics analysi...
New flow cytometry strategies allow researchers to address the study of biological nano-particles (BNP) up to the single-particle level.
-
NewIt is now possible to buy COVID-19 rapid selftest with delivery in 24/ 48 h through kitan...
With a reliability close to 100% (CE marking), rapid antigen self-tests become a routine preventive act against COVID-19
-
Press releaseAseBio announces that BIOSPAIN, Spain's leading biotech event, will be held at the end of ...
BIOSPAIN will be held at the Palacio de Congresos y Auditorio de Navarra-Baluarte in Pamplona, from 27 September to 1 October 2021, following a hybrid format
-
Press release
Spain leads research in advanced therapies with almost 120 clinical trials
Spain is positioned as a leader and benchmark country in advanced therapies, the cornerstone for the treatment of diseases such as cancer, where 62% of clinical trials are conducted.
-
NewMerck’s contribution in the field of Cultured Meat
Merck has ongoing research lines related to the management of resource scarcity and is driving innovation in the industrial field of 'clean meat' as a healthy, ethical and more planet-friendly
-
NewYsios Capital invests in Synendos Therapeutics
Synendos Therapeutics (Synendos) is a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders
-
NewProteos Biotech inaugurates new pharmaceutical plant in Barcelona
This project will enable it to expand and improve its CMO services, supporting customers in the manufacture of sterile pharmaceutical, medical device and cosmeceutical products
-
NewQualitecFarma starts clinical operations from its headquarters in USA
The company is dedicated to providing international support to the pharmaceutical and biotechnology industry in the development of its products
-
NewBioincubator: The right platform to bring your biotech project to life
The facilities of the Biotechnology Business Incubator (Bioincubator) are fully prepared for the start of activity, with state-of-the-art laboratories and equipment and very advantageous setup
-
NewMicroomics enlarge its team with two new members this year
The Spanish company has decided to reinforce the bioinformatics-statistical analyses and customer service
-
NewBCN HEALTH has published 14 studies in 2020 assessing the incidence and costs of illness o...
The company conducted retrospective studies based on records of patients diagnosed with the different diseases and treated in public and private hospitals in Spain between 2000 and 2017
